<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678011</url>
  </required_header>
  <id_info>
    <org_study_id>W20_182</org_study_id>
    <nct_id>NCT04678011</nct_id>
  </id_info>
  <brief_title>A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy</brief_title>
  <official_title>A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Mark's Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario de Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a personalised&#xD;
      surveillance and intervention protocol for patients with familial adenomatous polyposis (FAP)&#xD;
      that have undergone (procto)colectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial adenomatous polyposis (FAP) is characterized by formation of up to hundreds to&#xD;
      thousands of polyps throughout the entire colon and rectum. When left untreated, nearly all&#xD;
      patients with FAP develop colorectal cancer at a median age of 35-45 years. To prevent&#xD;
      colorectal cancer in patients with FAP, prophylactic colorectal surgery is performed. The&#xD;
      preferred surgical procedures for FAP are a restorative proctocolectomy with ileal pouch-anal&#xD;
      anastomosis (IPAA) or a subtotal colectomy with ileorectal anastomosis (IRA) or ileosigmoidal&#xD;
      anastomosis (ISA).&#xD;
&#xD;
      After both types of prophylactic colorectal surgery, subtotal colectomy with IRA/ISA or&#xD;
      proctocolectomy with IPAA, patients will require life-long surveillance because disease&#xD;
      progression and development of new adenomas in retained rectum, pouch or residual rectal cuff&#xD;
      will occur.&#xD;
&#xD;
      The 10-years risk of developing one or more adenomas in the rectum after IRA is 100% compared&#xD;
      to 33% in the pouch after IPAA. The risk of developing rectal cancer after IRA was found to&#xD;
      be 9% and 11% in two large studies with a median follow-up of 12.8 and 15 years,&#xD;
      respectively. One study showed that the 10-years risk of developing a carcinoma in the pouch&#xD;
      was 1%. As patients are usually operated at a young age, and nowadays have a long&#xD;
      life-expectancy, the actual cumulative life-time risk will presumably be higher.&#xD;
&#xD;
      The recently published ESGE (European Society of Gastrointestinal Endoscopy) polyposis&#xD;
      guideline recommends a one to two yearly endoscopic surveillance interval after prophylactic&#xD;
      colorectal surgery in FAP, both for patients that underwent IRA/ISA and IPAA, with removal of&#xD;
      all polyps &gt;5mm. This recommendation is based on expert-opinion, since no studies have been&#xD;
      reported comparing the efficacy and safety of different surveillance intervals. No advices&#xD;
      are provided on which patients will benefit from which surveillance interval.&#xD;
&#xD;
      With the proposed study, the investigators aim to provide evidence for personalized&#xD;
      endoscopic surveillance for patients with FAP that have undergone (procto)colectomy with&#xD;
      construction of an IRA/ISA or IPAA with the goal to prevent development of advanced neoplasia&#xD;
      (AN) by endoscopically removing lesions before they progress to AN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Advanced neoplasia</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of advanced neoplasia (advanced adenoma and cancer). An advanced adenoma is defined as size ≥ 10mm and/or high-grade dysplasia. This surveillance and intervention protocol will be considered successful when the incidence of advanced neoplasia is less than 5% after a study period of 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics polyps</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence and characteristics of polyps detected/removed in patients with IRA/ISA and IPAA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radicality of different endoscopic intervention techniques</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Rate of radical endoscopic interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility endoscopic interventions</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of lesions not amenable to endoscopic removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical interventions</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of surgical interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surveillance burden</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Surveillance burden (number of endoscopies per patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Incidence of endoscopy related complications</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Personalized surveillance and intervention protocol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized surveillance and intervention protocol</intervention_name>
    <description>This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.</description>
    <arm_group_label>Personalized surveillance and intervention protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with FAP treated at one of the participating centres.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of FAP, at least one of following: genetic diagnosis (proven APC germline&#xD;
             mutation) and/or clinical diagnosis (&gt;100 colorectal adenomas in combination with a&#xD;
             positive family history of FAP)&#xD;
&#xD;
          -  Have undergone prophylactic (procto)colectomy with IRA/ISA or IPAA&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to remove all polyps with an indication for removal during (multiple)&#xD;
             clearing endoscopies&#xD;
&#xD;
          -  Cancer at baseline endoscopy&#xD;
&#xD;
          -  Need for surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Dekker, MD, PhD</last_name>
      <phone>0031205661260</phone>
      <email>e.dekker@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Arthur Aelvoet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Evelien Dekker, MD, PhD</investigator_full_name>
    <investigator_title>Prof. dr. Evelien Dekker, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Endoscopic surveillance</keyword>
  <keyword>Endoscopic interventions</keyword>
  <keyword>Personalised care</keyword>
  <keyword>Gastrointestinal neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

